ReviewExpert opinion on biological therapy2007
The status of gene therapy for brain tumors.
Review in Expert opinion on biological therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 51 citations in OpenAlex.
- Chitosan-Based Polymeric Nanoparticles as an Efficient Gene Delivery System to Cross Blood Brain Barrier: In Vitro and In Vivo Evaluations.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Systematic Review of Pediatric Brain Tumors in Neurofibromatosis Type 1: Status of Gene Therapy.Cureus · 2022Review
- Reporter Genes for Brain Imaging Using MRI, SPECT and PET.International journal of molecular sciences · 2022Review
- A thirteen‑gene set efficiently predicts the prognosis of glioblastoma.Molecular medicine reports · 2019Article
- Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival.Biomaterials · 2016Article
- Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.Radiology · 2015Article
- Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.World journal of surgical oncology · 2013Article
- Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery.Biomaterials · 2013Article
- Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology.Neurosurgical focus · 2012Review
- Genetic therapy for the nervous system.Human molecular genetics · 2011Review
- Wild Type p53 gene sensitizes rat C6 glioma cells to HSV-TK/ACV treatment in vitro and in vivo.Pathology oncology research : POR · 2010Article
- Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.Cancer gene therapy · 2010Article
- Novel membrane-permeable contrast agent for brain tumor detection by MRI.Magnetic resonance in medicine · 2010Article
- Design and application of oncolytic HSV vectors for glioblastoma therapy.Expert review of neurotherapeutics · 2009Review
- Ultrasound for drug and gene delivery to the brain.Advanced drug delivery reviews · 2008Review
- Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.Cancer research · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The advent of gene therapy in the early 1990's raised expectations for brain tumor therapies; however, whereas clinical trials in patients with malignant gliomas provided evidence of safety, therapeutic benefit was not convincing. These early forays resembled the historical introductions of other therapies that seemed promising, only to fail in human trials. Nevertheless, re-study in the laboratory and retesting in iterative laboratory-clinic processes enabled therapies with strong biological rationales to ultimately show evidence of success in humans and become accepted. Examples, such as organ transplantation, monoclonal antibody therapy and antiangiogenic therapy, provide solace that a strategy's initial lack of success in humans provides an opportunity for its further refinement in the laboratory and development of solutions that will translate into patient success stories. The authors herein summarize results from clinical trials of gene therapy for malignant gliomas, and discuss the influence of these results on present thought in preclinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.